Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.

Stock Quote Today & Recent News NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Our first product ExoPTEN for acute spinal cord injury has been granted Orphan Drug Designation by the FDA.

Dr. Lior Shaltiel

Current News (TSXV:NRX)

NurExone Biologic Secures Master Cell Bank

GlobeNewswire 6 days ago

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

GlobeNewswire December 6, 2024

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 27, 2024

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

GlobeNewswire November 13, 2024

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

GlobeNewswire November 1, 2024

NurExone's Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

GlobeNewswire October 23, 2024
View More News ››

We are developing a unique and futuristic drug delivery system—exosomes deliver therapeutic cargo to tissues and organs, promoting a healing environment for neuroregeneration.

Dr. Lior Shaltiel

Opinion & Analysis (TSXV:NRX)

A potential breakthrough in spinal cord and optic nerve injury treatment

Research December 19, 2024

NurExone Biologic announces important test results

Research December 11, 2024

Revolutionary biopharma company makes waves across the globe

Lyndsay Malchuk July 10, 2024

ExoTherapy offers hope for treating acute spinal cord injuries

Brieanna McCutcheon  September 19, 2023
View More Opinion ››

Bullboard Posts (TSXV:NRX)

Exosome Based Therapies

NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to...
javaman12 - 5 hours ago

2025 Is The Critical Year For FDA Approval!

A near term 'Investigational New Drug' (IND) submission will be quickly followed by Phase I/IIa Human trials to help wheel chair...
javaman12 - 5 hours ago

🧬 Exosome Therapy Milestone 🧬

NurExone has secured a master cell bank for its innovative exosome-based therapy, ExoPTEN, targeting acute spinal cord injury (SCI...
cmarketinsights - 10 hours ago

Is This Biotech Now Poised For It's First Clinical Trials?

Imagine if it were possible to cure most neurological damage (like an accidental spinal paralysis, stroke or damage to the eye) with a...
javaman12 - 3 days ago

A New Frontier in Regenerative Medicine

A New Frontier in Regenerative Medicine NurExone Biologic Inc. (TSXV: NRX) , an Israeli biotech company, is developing a novel exosome...
cmarketinsights - 11 days ago

Analyst coverage report

Fundamental Research report: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment https://nurexone.com/wp...
Jolly09 - December 17, 2024
View more Bullboard ››

Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube

PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.

The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu